Insulin, Neurogenetics and Memory in Alzheimer's Disease

This study has been completed.

First Received: July 3, 2001 Last Updated: January 20, 2009 History of Changes

Sponsor:	Department of Veterans Affairs
Information provided by:	Department of Veterans Affairs
ClinicalTrials.gov Identifier:	NCT00018382

Purpose

This study examines the use of insulin-sensitizing compounds, as therapeutic agents for cognitive impairment in Alzheimer's disease.

Condition	Intervention	Phase
Alzheimer Disease	Drug: rosiglitazone	Phase II

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Efficacy Study
Official Title:	Insulin, Neurogenetics and Memory in Alzheimer's Disease: A Novel Therapeutic Approach

Resource links provided by NLM:

Genetics Home Reference related topics: Alzheimer disease

MedlinePlus related topics: Alzheimer's Disease Memory

Drug Information available for: Insulin Rosiglitazone Rosiglitazone Maleate

U.S. FDA Resources

Further study details as provided by Department of Veterans Affairs:

Study Start Date:	October 1999
Estimated Study Completion Date:	March 2003

Eligibility

Ages Eligible for Study:	55 Years to 80 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Men and women with mild Alzheimer's Disease without serious medical or psychiatric comorbid conditions.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00018382

Locations

United States, Washington
VA Puget Sound Health Care System
Seattle, Washington, United States, 98108

Sponsors and Collaborators

Department of Veterans Affairs

Investigators

Investigator:	Steven Kahn, M.D.
Investigator:	Sanjay Asthana, M.D.
Investigator:	Alfred Fujimoto, M.D.

More Information

No publications provided

Study ID Numbers:	AGCG-012-98S
Study First Received:	July 3, 2001
Last Updated:	January 20, 2009
ClinicalTrials.gov Identifier:	NCT00018382 History of Changes
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Alzheimer Disease
Nervous System Diseases
Physiological Effects of Drugs
Central Nervous System Diseases
Brain Diseases
Neurodegenerative Diseases
Pharmacologic Actions

Delirium, Dementia, Amnestic, Cognitive Disorders
Hypoglycemic Agents
Mental Disorders
Dementia
Tauopathies
Rosiglitazone

ClinicalTrials.gov processed this record on November 22, 2009